RealEndpoints

Manufacturers think CMS bars them from helping #Medicare patients afford their medicines. This is incorrect. Join the RE webinar to understand how patient services can help ensure affordable access for Medicare Beneficiaries. #marketaccess Register: bit.ly/39QcqVW

#CellTherapy and #GeneTherapy continue to grow with 2021 likely to be a record year for the number of regulatory decisions on new regenerative medicine products. Payers continue to watch the evolution of this space closely to address challenges. Read Here bit.ly/3cYeVWV

Equity and inclusion are fundamental to enable each of us to bring our best to our teams and organizations every day. Real Endpoints celebrates #internationalwomensday2021 as we salute our female colleagues. #ChooseToChallenge #WeCanDoIt #IWD2021 #IWD @womensday

As we approach #RareDiseaseDay the #RealEndpoints team thinks about tackling the tough issues around coverage and reimbursement and assuring #PatientAccess @rarediseaseday #raredisease #pharmaceuticals #marketaccess

Our CEO, @Berkowij joined @jimbojoyce and @HealthEugene for their podcast #TheShot of #DigitalHealth. Listen for a discussion on the early days of pharma market access, digital therapeutics, & #RealEndpoints revolutionary approach to VBAs. Watch here: bit.ly/373RtWm

Options, Expertise and Risk Tolerance say it all! The Real Endpoints Marketplace for #ValueBasedContracting addresses all of these. Contact us for expert support in developing and placing these arrangements. Read on our LinkedIn: bit.ly/2KUN1B8

Big approvals are starting in 2021.In a competitive heart failure market,will Verquvo be able to avoid market access challenges of products like Entresto (payer management,provider/patient access)Payers,providers,time will tell:bit.ly/3bY4JPh

With nearly 400 gene cell therapy candidates in clinical trials,FDA anticipating approving up to 20 gene cell therapies annually by 2025-pricing/market access will be a major focus.RE has expertise in tackling the road to reimbursement. bit.ly/2X4rLvc

ICER's just released Unsupported Drug Price Increase Report is bound to stir controversy in trying to determine whether new clinical evidence supports "substantial" price increases for drugs with a large impact on U.S. drug spending. Interesting reading - icer.org/wp-content/uploads/…

2021 drug price increases are coming in at 3.3% on average, exceeding the 1.2% 2020 inflation rate. Will the ability to take drug price increases survive a new administration? Read here: bit.ly/2MAxEyd

Our CCO, Dr Barlow, offers a valuable playbook for securing sustainable reimbursement for innovative gene therapies in this article. Payers will continue to seek & implement solutions to address the challenges of one-time high cost gene therapy treatments. bit.ly/2Mx1cNf

About 70 drugmakers raised prices in the U.S. on Friday -avg. increase of 3.3%. Inflation registered at 1.2% for the most recent 12 mths. This year’s avg. price increase is lower than a yr ago, when more than 60 companies raised prices by an avg. of 5.8%. on.mktw.net/387M7tQ

The Real Endpoints team thanks all of our colleagues, clients and friends for pulling together this year. We wish you and your families a safe and happy holiday. Looking forward to the sun coming out on a new year - one filled with good health and good fortune.

Finally! The CMS Final Rule revising average manufacture price & "best price" reporting requirements will be a potential game-changer paving the way for a new generation of innovative contracting methodologies based on value. bit.ly/34zrfty #valuebasedpricing #cms